<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H72F5DE808E6D429ABA95D08DBD75BA16" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 9011 IH: Updated Drug Labeling for Patient Safety Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-09-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 9011</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220928">September 28, 2022</action-date><action-desc><sponsor name-id="M001200">Mr. McEachin</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to establish a process to allow the holders of abbreviated new drug applications to make labeling changes to include new or updated safety-related information, and for other purposes.</official-title></form><legis-body id="H5C95DAE4BD124E859D9CD05AA7A6030F" style="OLC"><section id="HDBD8B92D78634B2B879D5C69F0FF8751" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Updated Drug Labeling for Patient Safety Act</short-title></quote>. </text></section><section id="HCF15DCE769B44EFEBF827141F54AAA27"><enum>2.</enum><header>Safety labeling changes initiated by ANDA holders</header><subsection id="H34165F72292D41E490391F6F8C7D8D6E"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) is amended by adding at the end the following: </text><quoted-block style="traditional" id="H5206994A13AF4A3CB7DDD00ED3DC2F88" display-inline="no-display-inline"><paragraph id="HF38E016021E848BBA6A070447597454E" indent="up1"><enum>(14)</enum><text display-inline="yes-display-inline">Notwithstanding paragraphs (2)(A)(v), the Secretary shall establish a process to allow the holder of an abbreviated new drug application to change the labeling of the drug that is the subject of the application to include new or updated safety-related information, including a process to make such changes prior to being approved by the Secretary. </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HB7B1CF52554E49C79FCE1D9B9460401D"><enum>(b)</enum><header>Regulations</header><paragraph id="H105E65F40BCE48D092C8F73F0AE97515"><enum>(1)</enum><header>In general</header><text>Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services shall issue a final rule to implement paragraph (14) of section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>), as added by subsection (a). </text></paragraph><paragraph id="H01ADA6B071A9417C8DE6AE6132722B99"><enum>(2)</enum><header>Contents</header><text display-inline="yes-display-inline">The final rule issued under paragraph (1) shall include a process for conforming the labeling of a drug that is labeled pursuant to such paragraph (14), the listed drug (as such term is used in such section 505(j)), and other drugs approved under such section 505(j) that reference such listed drug. </text></paragraph><paragraph id="H0E7F0FF5500C482F9BC5E4958B8B2731"><enum>(3)</enum><header>Effective date</header><text>The final rule issued under paragraph (1) shall become effective not later than 180 days after the date on which such final rule is issued.</text></paragraph></subsection></section></legis-body></bill> 

